MannKind Corp. Equity-NMS: MNKD

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$3.62
Open :	$3.69
Today's high :	$3.69
Today's low :	$3.54
52W low :	$3.52
52W high :	$7.63
1Y :	-32.79%
5Y :	101.64%
EPS(TTM): :	0.1
Shares O/S :	303.93 M
Market cap :	1.09 B

What is the share price of MannKind Corp. today?

MannKind Corp. (MNKD) share price as of July 6, 2025, is $3.6. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of MannKind Corp.?

Yes, Indian Investors can invest in the MannKind Corp. (MNKD) Share by opening an international trading account with Angel One.

How can I purchase MannKind Corp. shares in India?

Purchasing MannKind Corp. (MNKD) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying MannKind Corp. (MNKD) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of MannKind Corp.?

Yes, you can purchase fractional shares of MannKind Corp. (MNKD) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of MannKind Corp.?

The market capitalization of MannKind Corp. on July 6, 2025, is $1.09 B.

In which sector MannKind Corp. belongs?

MannKind Corp. operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in MannKind Corp. stocks?

In order to invest in MannKind Corp. (MNKD) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

MannKind Corporation is focused on the development and commercialization of inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company's technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices. In its endocrine business unit, it commercializes two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its pipeline products include Pediatric Afrezza (insulin human) Inhalation Powder, MNKD-101 and MNKD-201.